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Abstract
Objective: Urinary nerve growth factor (NGF) has gained great interest in 
detecting detrusor overactivity (DO) in patients with overactive bladder 
syndrome. However, the source of urinary NGF has not been fully elucidated. 
We investigated the relationship of urinary NGF levels and NGF expression 
in the urothelium and suburothelium of patients with idiopathic DO.
Materials and Methods: Bladder tissues not involving the muscle layer 
were obtained from 18 patients with urodynamic DO with or without blad-
der outlet obstruction. Urine samples at full bladder were also collected 
for urinary NGF measurement. Fourteen bladder and urine samples 
obtained from patients with stress urinary incontinence but no lower uri-
nary tract symptoms served as controls. Urinary NGF levels were mea-
sured by ELISA. Expression of NGF in the urothelium was measured by 
immunohistochemical staining using anti-human antibody, and stained 
sections were captured by a digital image system. Correlation analysis 
between the urothelial NGF levels in the bladder tissue and urinary NGF/
creatinine (Cr) were performed.
Results: Urinary NGF/Cr levels were significantly higher in DO patients 
(0.78 ± 1.26) compared with the control group (0.01 ± 0.02; p = 0.02). 
However, NGF expression in the DO urothelium (125.87 ± 21.79) were not 
significantly higher than the controls (135.60 ± 13.50; p = 0.142). 
Correlation between urinary and urothelial NGF levels were not significant 
in both controls and patients with DO (Spearman’s r = –0.32, p = 0.26 and 
Spearman’s r = 0.28, p = 0.22, respectively).
Conclusion: DO patients have higher urinary NGF/Cr levels than controls. 
However, urothelial NGF expression was no different between the two groups. 
The results suggest elevated urinary NGF levels in DO patients might not 
be due to urothelial NGF overproduction. [Tzu Chi Med J 2010;22(4):
165–170]
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1. Introduction
Nerve growth factor (NGF) has been implicated as a 
chemical mediator of pathology-induced changes in 
C-fiber afferent nerve excitability and reflex bladder 
activity [1,2]. The levels of neurotrophic factors in-
cluding NGF increase in the bladder after spinal cord 
injury [1,3], and increased levels of NGF have been de-
tected in the lumbosacral spinal cord and dorsal root 
ganglia of rats after spinal cord injury [4]. It has been 
demonstrated that chronic administration of NGF into 
the spinal cord or chronic administration of NGF into 
the bladder of rats induces bladder hyperactivity and 
increases the firing frequency of dissociated bladder 
afferent neurons [2,4–7].
The stimulus for NGF production in the bladder is 
due in part to stretch of the bladder after bladder 
outlet obstruction (BOO). Stretching bladder smooth 
muscle cells in vitro increases mRNA for NGF and 
stimulates the secretion of NGF [8]. Protein synthesis 
inhibitors suppress the stretch-evoked secretion. These 
results indicate that mechanical stretch activates cel-
lular machinery for the production and secretion of 
NGF which in turn acts on sensory nerves in the blad-
der to enhance afferent input to the spinal cord and 
enhance reflex bladder activity.
Human bladder tissue obtained from subjects un-
dergoing suprapubic prostatectomy for outlet obstruc-
tion had more than twice the level of NGF than tissue 
obtained by cystoscopy from patients who were being 
evaluated for conditions other than obstruction [9]. 
There could be a difference of NGF concentration in 
the detrusor and superficial bladder tissue. Increased 
levels of urinary NGF have also been detected in pa-
tients with BOO exhibiting overactive bladder (OAB) 
symptoms. Following successful medical treatment 
that reduced the symptoms, the urinary NGF levels 
were reduced [10]. It was concluded that urinary NGF 
levels can be used as a biomarker for OAB and detru-
sor overactivity (DO) and as a method for assessing 
successful therapies.
There are only a few clinical studies of NGF concen-
trations in bladder tissue. Lowe et al found that the 
levels of NGF were higher in samples from patients 
with painful bladder conditions than in controls. Im-
munostaining showed increased NGF expression in 
the urothelium, which was most marked in patients 
with idiopathic sensory urgency [11]. However, a recent 
study measuring NGF concentrations (using ELISA) 
in superficial bladder biopsies from 12 women with 
DO and 15 who did not have urodynamic DO did not 
show a significant correlation between tissue NGF 
levels and DO [12].
Urothelial dysfunction is known to act as a key con-
tributing factor in interstitial cystitis/painful bladder 
syndrome (IC/PBS). Whether urothelial dysfunction ex-
ists in OAB has not been elucidated. A previous study 
has shown that adherens junctions are decreased in 
patients with DO and BOO [13,14]. It is likely that 
urothelial dysfunction also plays a role in DO and 
OAB. Whether the elevated urinary NGF in the blad-
ders of patients with DO comes from the urothelium 
or detrusor remains undetermined. How the NGF pro-
tein is excreted into the vesical lumen has also not 
been explored. We thought that urothelial dysfunction 
could be a cause for the increased NGF level in the 
urine of patients with DO. This study investigated the 
relationship of urinary NGF levels and NGF expression 
in the urothelium of patients with DO.
2. Materials and methods
2.1. Patients and specimens
Bladder tissue not involving the muscle layer was ob-
tained from 18 patients with urodynamic DO who un-
derwent intravesical botulinum toxin A injection for 
urinary incontinence. Urine samples at full bladder 
were also collected for urinary NGF measurement. 
Fourteen bladder and urine samples obtained from pa-
tients with stress urinary incontinence but no lower 
urinary tract symptoms served as controls. This study 
was approved by the institutional review board of the 
hospital. Informed consent was obtained before the 
surgical procedure was performed.
2.2. Measurement of urinary NGF levels
Measurement of urinary NGF levels was performed 
by the ELISA method using nondiluted urine samples. 
Voided urine was put on ice immediately and centri-
fuged at 3000g for 10 minutes at 4°C. The superna-
tant was separated into aliquots in 1.5 mL tubes and 
preserved in a −80°C freezer. At the same time, 3 mL 
urine was taken to measure the urinary creatinine 
(Cr) level. The urinary NGF concentration was deter-
mined using the Emax ImmunoAssay System (Promega, 
Madison, WI, USA) with a specific and highly sensitive 
ELISA kit, which has a minimum sensitivity of 7.8 pg/
mL. The amount of NGF in urine samples which had 
levels below the detection limits of the NGF assay was 
extracted from an NGF standard curve. We ran sam-
ples in triplicate. If the urinary NGF levels were not 
consistent after three measurements, the assay was 
repeated and the values averaged. When the urinary 
NGF concentration was higher than the upper detec-
tion limit (250 pg/mL), the urine samples were diluted 
to fit the detection limit. For urine samples with NGF 
concentrations lower than the detectable limit but 
above zero, a concentration method was performed 
using a column-protein concentration kit (Amicon Ultra-
15; Millipore, Billerica, MA USA). The total urinary NGF 
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levels were further normalized by the concentration 
of urinary creatinine (NGF/Cr) level [15].
2.3. Immunohistochemistry staining of 
urothelium NGF
The urinary bladder specimens were immersed and 
fixated for 1 hour in an ice-cold solution of 4% for-
maldehyde in phosphate buffered saline (pH 7.4) 
and rinsed with ice-cold phosphate buffered saline 
containing 15% sucrose overnight. Biopsy specimens 
were embedded in OCT medium (Miles, Elkhart, IN, 
USA) and stored at −80°C. Four sections per specimen 
were cut in a cryostat at 8 μm and collected on poly-
sine slides. Sections were post-fixed in acetone at 
−20°C and blocked with blocking solution (BioGenex 
Laboratories Inc., San Ramon, CA, USA). The sec-
tions were incubated overnight at 4°C with primary 
antibodies of anti-human NGF antibody (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA). After rinsing 
the sections with 1% Tween-20 phosphate-buffered 
saline, DAB staining was performed by the Super 
Sensitive Polymer-HRP IHC Detection System (Bio-
Genex Laboratories Inc.). NGF stained bladder sec-
tions were captured by digital image system and the 
images were converted to gray-level. Density of NGF 
expression was quantified with the Image J software, 
developed by the National Institutes of Health. Three 
tissue sections per patient were quantified and the 
mean values were used in the subsequent statistical 
analyses.
2.4. Statistical analyses
Correlation analysis between the bladder tissue NGF 
in the urothelium and urinary NGF/Cr were performed 
by Pearson’s correlation. The concentrations of urinary 
NGF and bladder tissue NGF were compared by the 
Mann-Whitney test. A p value < 0.05 was considered 
significant.
3. Results
3.1. Urinary and urothelial NGF in DO and 
controls
Urinary NGF/Cr levels were significantly higher in 
patients with DO (0.78 ± 1.26 pg/mg) than controls 
(0.01 ± 0.02 pg/mg; p = 0.02). However, NGF expres-
sion in the DO urothelium (125.87 ± 21.79) were not 
significantly higher than controls (135.60 ± 13.50; 
p = 0.142; Table 1). Expression of NGF in the urothe-
lium of the bladder of DO and controls are shown in 
Fig. 1.
3.2. Correlation between urine NGF and 
bladder tissue NGF expression
The urinary NGF/Cr levels were not correlated with 
urothelial NGF expression in both controls and pa-
tients with DO (Spearman’s r = –0.32, p = 0.26 and 
Spearman’s r = 0.28, p = 0.22, respectively; Fig. 2).
4. Discussion
The results of this study revealed that although urinary 
NGF levels were higher in DO bladders, urothelium 
NGF expression was not increased in the DO bladders 
compared with the controls. It is possible that the 
elevated urinary NGF in the DO bladder is caused by 
excretion of NGF from smooth muscle cells or infil-
trated inflammatory cells into the urine through the 
dysfunctional urothelium.
NGF is a small secreted protein that induces the 
differentiation and survival of particular target neu-
rons. NGF can be produced from the urinary bladder 
through protein kinase C and protein kinase A-
dependent intracellular pathways to play physiologic 
and pathophysiologic roles in the lower urinary tract 
[16]. Exogenous NGF may sensitize afferent nerves 
and induce bladder hyperactivity [1,2], and is asso-
ciated with the mechanical stretch and reflex blad-
der activity [17]. Normally, NGF exists in the afferent 
nerves and ganglia of the bladder wall and is respon-
sible for a normal sensation of bladder distention and 
conduction of abnormal sensory input [8].
In a recent study using a transgenic mouse model, 
chronic urothelial NGF overexpression led to neuro-
nal proliferation, focal increases in urinary bladder 
mast cells, increased urinary bladder reflex activity, 
and pelvic hypersensitivity. Overexpression of NGF in 
mouse urothelium led to neuronal hyperinnervation, 
pelvic sensitivity, and changes in urinary bladder 
function [18].
Visceral epithelia have been demonstrated to be a 
major source of NGF production, and NGF may regu-
late the function of adult visceral sensory and motor 
neurons [19]. Stretching of the urothelium during blad-
der distention might induce production of NGF in the 
Table 1 — Bladder tissue nerve growth factor (NGF) 
expressions and urine NGF in patients with detrusor 
overactivity (DO) and controls*
 Controls DO p (control 
 (n = 14) (n = 18) vs. DO)
Urothelial NGF 135.60 ± 13.50 125.87 ± 21.79 0.142
Urine NGF (pg/mL) 0.85 ± 1.68 40.70 ± 56.60 0.006†
Urine NGF/Cr 0.01 ± 0.02 0.78 ± 1.26 0.020†
 (pg/mg)
*Data presented as mean ± standard deviation; †p < 0.05. Cr = creatinine.
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Fig. 1 — Immunohistochemical staining of nerve growth factor in the urothelium and suburothelium in the bladder tissues 
of patients with detrusor overactivity (overactive bladder) and controls. The density of nerve growth factor expression 
was calculated by Image J software.
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Fig. 2 — Correlation between urinary and bladder tissue nerve growth factor expression in: (A) control bladders; and 
(B) detrusor overactivity bladders.
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bladder tissue and secretion into the urine. It is ra-
tional to hypothesize that NGF produced in the blad-
der wall can be secreted into the bladder lumen [17]. 
Although the NGF levels in the bladder tissue and urine 
might not correlate well, an interaction between uri-
nary NGF and sensory fibers, as well as an effect on 
detrusor hyperactivity, is likely.
Using immunohistochemistry study, basal level NGF 
expression in the urothelium was also noted in con-
trols, indicating that a considerable amount of NGF is 
normally present in the urothelium. The higher uri-
nary NGF in DO patients is possibly due to leakage 
from the bladder wall into the vesical lumen through 
a dysfunctional urothelium.
Increased levels of NGF have also been reported in 
the bladder urothelium and smooth muscle and urine 
of patients with IC/PBS, sensory urgency and DO 
[11,12,20]. In patients with neurogenic DO, the NGF 
levels in bladder tissue increased and decreased after 
detrusor botulinum toxin A injection in association 
with a decrease in detrusor contractility [21]. Previous 
studies of NGF in OAB or DO usually measured the 
bladder tissue levels. NGF bladder levels were elevated 
in patients with idiopathic DO, men with benign pro-
static hyperplasia, and women with IC/PBS [8].
Our previous study has shown that the urinary NGF 
level may increase in not-full bladders of patients with 
DO but not in normal controls. In fully distended blad-
ders, the urinary NGF levels were slightly increased 
in normal controls [22]. This observation implies that 
the urothelium acts as a barrier to prevent NGF leaking 
out of the bladder wall in the resting state. In a fully 
distended bladder, however, the highly secreted NGF 
might leak into the visceral lumen, at higher levels in 
DO bladders and lower levels in control bladders. The 
results of this study showing highly expressed bladder 
tissue NGF and low urinary NGF levels in the controls 
further demonstrate that NGF is normally present in 
the bladder tissue and not leaked out into urine.
Although it seems rational to hypothetically link 
the elevated urinary NGF levels with urothelial dys-
function in DO bladders, the cause for the higher NGF 
expression in the control bladders remains unknown. 
Interestingly, our observation is compatible with that 
of Birder et al [12]. Previous studies from animal mod-
els all showed elevated bladder tissue NGF expression 
in cystitis and BOO models [7,23,24]. It is possible 
that part of the elevated NGF expression in those mod-
els originated from the detrusor. One study measur-
ing human detrusor NGF concentrations also revealed 
that the mean NGF content was significantly higher in 
unstable tissues compared with that in the normal blad-
der [16]. It is possible that detrusor NGF content in 
response to BOO or chronic inflammation might con-
tribute to elevated bladder tissue NGF concentration.
Another possibility is that the increased NGF pro-
duction in response to stimulation is rapidly taken up 
by sensory nerves and transported through the central 
nervous system in a retrograde fashion [25]. The mea-
sured bladder tissue NGF, in fact, reflects the basic 
concentrations needed for physiological needs, both 
in controls and DO bladders. The source of increased 
urinary NGF might be produced from detrusor or in-
filtrated inflammatory cells. Urothelial dysfunction 
might exist in DO patients and cause NGF to leak from 
bladder tissue into urine. These speculations need 
further investigation.
This study was limited by a lack of protein mea-
surements of NGF in bladder tissue. Although immu-
nohistochemistry can reflect the NGF protein content 
in sensory nerve fibers, it cannot reflect the true NGF 
concentrations in the bladder wall. Using ELISA to 
measure NGF concentrations might be helpful to fur-
ther clarify the relationship between bladder tissue and 
urine NGF levels. Further, we did not measure the de-
trusor NGF concentrations in this study. Whether the 
elevated urinary NGF levels are due to high detrusor 
NGF expression in DO bladders remains unknown. 
Because the calculation methods between NGF con-
centrations in the urothelium and suburothelium were 
different, it is not appropriate to compare the NGF con-
centrations between these two sites using numerical 
data.
This study has shown that DO patients have higher 
urinary NGF than controls. However, urothelial NGF 
level was no different between the two groups. This 
result suggests that increased urinary NGF in DO 
patients might not be due to higher urothelial NGF 
expression.
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